TD Cowen raises target for Regeneron stock to USD 980 from USD 960

Published on 10/23/2026 at 11:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron reports third-quarter results on October 30, 2026 before the open. Regeneron stock costs EUR 727.70 on October 23, 2026.

Pipeline and earnings dates

TD Cowen lifted its Regeneron target from USD 960 to USD 980 on October 21, 2026.
Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year.
Regeneron stock trades at EUR 727.70 at 11:32 a.m. CEST at Lang & Schwarz on October 23, 2026.
Third-quarter results are scheduled for October 30, 2026.

Pop-Art-Comic-Illustration eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor — Regeneron Pharma US75886F1075 präsentiert eine farbenfrohe Pop-Art-Comic-Szene eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor, Illustration mit AI erstellt.

Regeneron Pharmaceuticals (ISIN US75886F1075) is trading at EUR 727.70 at Lang & Schwarz on October 23, 2026 at 11:32 a.m. CEST. According to Markets Insider on October 21, 2026, TD Cowen raised its price target for Regeneron from USD 960 to USD 980 and maintained a Buy rating.

Results set the next test

Regeneron's next scheduled catalyst is its third-quarter report. The company said in an official release dated September 24, 2026 that it will publish results on October 30 before the U.S. financial markets open and host a conference call at 8:30 a.m. ET.

The timing matters because the last reported quarter delivered a sizable year-over-year comparison. MarketBeat reported that second-quarter 2026 revenue was USD 4.29 billion, up 16.70 percent from the same quarter a year earlier. Reported earnings per share were USD 14.29 against a consensus estimate of USD 10.16.

Three dates chart the story

On July 30, 2026, Regeneron reported second-quarter revenue of USD 4.29 billion and earnings per share of USD 14.29, according to MarketBeat. On September 24, 2026, Regeneron announced its October 30 reporting date. On October 21, 2026, TD Cowen raised its target from USD 960 to USD 980.

What does the target signal?

The USD 20.00 increase points to a more constructive view of Regeneron's near-term commercial outlook, but the October 30 report remains the next measurable test. The company profile identifies biotechnology as its industry and lists EYLEA, Dupixent and Libtayo among its major medicines.

Upcoming reporting date

Regeneron will report third-quarter 2026 financial and operating results on October 30, 2026, before the U.S. market open, with the conference call scheduled for 8:30 a.m. ET. The company is listed on Nasdaq under the ticker REGN.

Stock price in euros

At Lang & Schwarz, Regeneron stock was trading at EUR 727.70 on October 23, 2026 at 11:32 a.m. CEST. The primary Nasdaq quote was USD 819.09 at 4:00 p.m. EDT on October 22, 2026, while the 52-week range was USD 572.75 to USD 859.34.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.